Bariatric Surgery and Microvascular Complications of Type 2 Diabetes Mellitus

被引:0
作者
Sabrina Jackson
Carel W. le Roux
Neil G. Docherty
机构
[1] University College Dublin,Diabetes Complications Research Centre, Conway Institute of Biomolecular and Biomedical Research, School of Medicine and Medical Sciences
来源
Current Atherosclerosis Reports | 2014年 / 16卷
关键词
Retinopathy; Nephropathy; Neuropathy; Bariatric surgery; Type 2 diabetes;
D O I
暂无
中图分类号
学科分类号
摘要
Metabolic dysregulation is the defining characteristic of type 2 diabetes mellitus (T2DM) and can give rise to microvascular complications, specifically retinopathy, nephropathy and neuropathy. Pharmacological targeting of risk factors for microvascular complications can yield therapeutic gains, particularly in relation to retinopathy and nephropathy. Bariatric surgery is superior to intensified pharmacotherapy in relation to glycaemic control and can remediate dyslipidaemia and hypertension. Consequently, evidence of the effect of bariatric surgery on microvascular complications is now emerging in the literature. Examination of the recent published evidence base (covering the period 2011–2014) on the effects of bariatric surgery on microvascular complications reveals further evidence supportive of the efficacy of bariatric surgery in preventing the incidence and progression of albuminuria and arresting renal functional decline. Data on retinopathy are more ambivalent potentially representing the potential in some cases for a degree of surgery associated reactive hypoglycaemia to detract from the benefits of amelioration of hyperglycaemia. A significant gap in the literature remains in relation to the effects of surgery on diabetic neuropathy. Overall, there is a pressing need for prospective randomised controlled trials examining long-term microvascular outcomes following bariatric surgery in patients with T2DM.
引用
收藏
相关论文
共 150 条
[1]  
Danaei G(2011)National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants Lancet 378 31-40
[2]  
Finucane MM(2013)Economic costs of diabetes in the U.S. in 2012 Diabetes Care 36 1033-46
[3]  
Lu Y(2008)An integrated view of insulin resistance and endothelial dysfunction Endocrinol Metab Clin N Am 37 685-711
[4]  
Muniyappa R(2001)Biochemistry and molecular cell biology of diabetic complications Nature 414 813-20
[5]  
Iantorno M(2013)Mechanisms of diabetic complications Physiol Rev 93 137-88
[6]  
Quon MJ(2005)Diabetic nephropathy: diagnosis, prevention, and treatment Diabetes Care 28 164-76
[7]  
Brownlee M(2003)Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64) Kidney Int 63 225-32
[8]  
Forbes JM(2013)Kidney disease and increased mortality risk in type 2 diabetes J Am Soc Nephrol 24 302-8
[9]  
Cooper ME(2013)Pathophysiology of diabetic retinopathy ISRN Ophthalmol 2013 343560-63
[10]  
Gross JL(2001)UKPDS 50: risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis Diabetologia 44 156-93